Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

This study is testing a personalized cancer vaccine called NECVAX-NEO1 in combination with standard chemotherapy and immunotherapy in people with newly diagnosed, early-stage triple-negative breast cancer (a type that tends to be more aggressive and doesn't respond to hormone therapies). The vaccine is made from proteins unique to each person's tumor. **You may be eligible if...** - You are 18 or older (male or female) - You have been newly diagnosed with stage II or III triple-negative breast cancer - You are a candidate for standard neoadjuvant (pre-surgery) chemotherapy plus immunotherapy - Your tumor is accessible for biopsy and surgery - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have had another cancer in the last 5 years - You have had an organ transplant - You have an active autoimmune disease requiring treatment - You have active HIV, hepatitis B, or hepatitis C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.